Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: Results from the BAX326 Pivotal Study

Haemophilia

Volumn 20, Issue 3, 2014, Pages 362-368

  Windyga, J ^a   Lin, V W ^b   Epstein, J D ^b   Ito, D ^b   Xiong, Y ^b   Abbuehl, B E ^c   Ramirez, J H ^d  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c BAXTER INNOVATIONS GMBH   (Austria)

^d CENTRO MÉDICO IMBANACO   (Colombia)

Author keywords

BAX326; Haemophilia B; Health related quality of life; Prophylaxis; RFIX

Indexed keywords

BAX 326; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ADULT; ARTHROPATHY; ARTICLE; BLEEDING; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL INTERACTION; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; CROSSOVER PROCEDURE; METABOLISM; MIDDLE AGED; QUESTIONNAIRE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CROSS-OVER STUDIES; FACTOR IX; FEMALE; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84898899925     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12315     Document Type: Article

References (20)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
2. Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost 2011; 106: 398-404.
3. Franchini M, Frattini F, Crestani S, Bonfanti C. Haemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother 2012; 13: 2053-63.
4. Noone D, O'Mahony B, vanDijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50.
5. Den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15: 83-90.
6. von Mackensen S, Gringeri A, Siboni SM, Mannucci PM. Health-related quality of life and psychological well-being in elderly patients with haemophilia. Haemophilia 2012; 18: 345-52.
7. Tusell J, Cid AR, Sosa R, Villar A, Lucia JF. Haemophilia prophylactic treatment in Spain. Haemophilia 2002; 8: 729-30.
8. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
9. Hartl HK, Reitter S, Eidher U, Ramschak H, Ay C, Pabinger I. The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. Haemophilia 2008; 14: 703-8.
10. Douma-van Riet DC, Engelbert RH, Van Genderen FR, Ter Horst-De Ronde MT, de Goede-Bolder A, Hartman A. Physical fitness in children with haemophilia and the effect of overweight. Haemophilia 2009; 15: 519-27.
11. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
12. Poon JT. The Hemophilia Utilization Group Study (HUGS-Vb): Health-related quality of life in hemophilia B. Poster presented at: International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting; May 21, 2011; Baltimore, MD.
13. Lou M. The Hemophilia Utilization Group Study (HUGS Vb): Characterization of baseline data. Poster presented at: National Hemophilia Foundation 62nd Annual Meeting; November 11, 2010; New Orleans, LA.
14. Windyga J, Lissitchkov T, Stasyshyn O et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicenter phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIXlevel ≤2%) haemophilia B. Haemophilia 2013; DOI: 10.1111/hae.12228. [Epub ahead of print]
15. Ware JE Jr, Gandek B, Kosinski M. SF-36 Health Survey: Manual & Interpretation Guide. Lincoln, RI: QualityMetric Incorporated, 1993, 2000.
16. Lindvall K, Von Mackensen S, Berntorp E. Quality of life in adult patients with haemophilia - a single centre experience from Sweden. Haemophilia 2012; 18: 527-31.
17. Wang T, Zhang L, Li H, Zhao H, Yang R. Assessing health-related quality-of-life in individuals with haemophilia in China. Haemophilia 2004; 10: 370-5.
18. Klamroth R, Pollmann H, Hermans C et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia 2011; 17: 412-21.
19. Trippoli S, Vaiani M, Linari S, Longo G, Morfini M, Messori A. Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia. Haematologica 2001; 86: 722-8.
20. Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia 2001; 7: 53-63.